Acasti Pharma Inc. reports fiscal 2009 results and scientific update

    LAVAL, QC, June 30 /CNW Telbec/ - Acasti Pharma Inc. ("Acasti") today
announced its financial results for the nine-month period ended February 28,
2009 (fiscal year end) and provides a scientific update.
    "During the fiscal year, the Company has made significant progress in the
scientific research and development programs and has achieved several
value-creating milestones within the over-the-counter ("OTC"), medical food
and prescription drug programs," said Dr. Tina Sampalis, Acasti Pharma's
President. "Acasti's objective is to research, develop and license active
pharmaceutical ingredients designed to prevent and treat cardiovascular
disease," she added.

    Update on recent Highlights

    - Under the OTC program, product development has now been completed.
      According to the strategic business development plan, negotiations with
      prospective development partners are ongoing to evaluate a monotherapy
      and two formulations.
    - With regards to the medical food program, product development has been
      completed and the Company has successfully obtained a positive review
      from the Food and Drug Administration ("FDA") for medical food product
      opportunities. The Company is discussing with potential partners in
      order to evaluate customized formulations.
    - Under the prescription drug development program, the product
      development under Good Laboratory Practice ("GLP") has now been
      completed for the prescription drug candidates. The Company has
      received FDA guidance for an Investigational New Drug in the United
      States and a Clinical Trial Application in Canada. The FDA approved the
      general outline of the development plan and detailed protocols are in
      preparation for submission. The Company has during its fiscal year,
      initiated preclinical toxicity, dose response and efficacy studies in
      animals required for regulatory submissions. Studies are progressing
      according to timelines and budgets.

    Financial Results(1)

    - In the nine-month period ended February 28, 2009, Acasti Pharma created
      a loss of $782,000.
    - At February 28, 2009, the Company had cash, cash equivalents and short-
      term investments totaling $1,595,000 net of accounts payable to the
      parent company.
    - Acasti Pharma is researching and developing novel active pharmaceutical
      ingredients for cardiovascular applications and the expenses can be
      mainly attributed to R&D expenses and administrative expenses,
      initially and previously supported by the parent company Neptune
      Technologies & Bioressources Inc.

    Milestones Anticipated for 2009 and 2010

    - Submission of a investigational new drug ("IND") application in the
      United States with completed animal pharmacology and toxicology
      studies, pharmacokinetics, mechanism of action, GMP chemistry,
      manufacturing, control and proposed clinical protocols information.
    - Submission of a clinical trial application ("CTA") in Canada required
      for the initiation of clinical trials of experimental drug development.
    - Partnership with a pharmaceutical company to evaluate over-the-counter
      and/or medical food formulations.

    (1) Please find complete financial information on

    About Acasti Pharma Inc.

    Acasti Pharma is developing a product portfolio of proprietary novel
long-chain omega-3 phospholipids. Phospholipids are the major component of
cell membranes and are essential for all vital cell processes. They are one of
the principal constituents of High Density Lipoprotein (good cholesterol) and
play, as such, an important role in modulating cholesterol efflux. Acasti
Pharma's proprietary novel phospholipids carry and functionalize the
polyunsaturated omega-3 fatty acids EPA and DHA, which have been shown to have
substantial health benefits and which are stabilized by potent antioxidants.
Acasti Pharma is focusing initially on treatments for chronic cardiovascular
conditions within the over-the-counter, medical food and prescription drug
    Acasti Pharma is a subsidiary of Neptune Technologies & Bioressources

    NASDAQ does not accept responsibility for the adequacy or accuracy of
    this press release. Neither TSX Venture Exchange nor its Regulation
    Services Provider (as that term is defined in the policies of the TSX
    Venture Exchange) accepts responsibility for the adequacy or accuracy of
    this release.

    Statements in this press release that are not statements of historical or
current fact constitute "forward-looking statements" within the meaning of the
U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities
laws. Such forward-looking statements involve known and unknown risks,
uncertainties, and other unknown factors that could cause the actual results
of the Company to be materially different from historical results or from any
future results expressed or implied by such forward-looking statements. In
addition to statements which explicitly describe such risks and uncertainties,
readers are urged to consider statements labeled with the terms "believes,"
"belief," "expects," "intends," "anticipates," "will," or "plans" to be
uncertain and forward-looking. The forward-looking statements contained herein
are also subject generally to other risks and uncertainties that are described
from time to time in the Company's reports filed with the Securities and
Exchange Commission and the Canadian securities commissions.

For further information:

For further information: Toni Rinow, Ph.D., MBA, Corporate Development &
Investor Relations, Acasti Pharma Inc., (450) 687-2262,

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890